Drug Profile

Interleukin 12 gene therapy - Regulon

Alternative Names: LipoVIL12

Latest Information Update: 02 Oct 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Regulon
Class Antineoplastics; Cytokine genes; Gene therapies; Immunotherapies; Interleukins
Mechanism of Action Immunomodulators; Interleukin 12 stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Discontinued Glioblastoma

Most Recent Events

30 Sep 2015 Discontinued - Phase-I/II for Glioblastoma in Germany (Parenteral)
30 Sep 2015 Discontinued - Phase-II for Glioblastoma in Greece (Parenteral)
08 Dec 2014 Interleukin 12 gene therapy licensed to In Ovations Holdings

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com